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Human C1q is the first recognition molecule of the classical pathway of the 
complement system. C1q has a characteristic tulip-like overall structure where N-
terminal collagenous stalk (CLR) is followed by a heterotrimeric C-terminal globular 
(gC1q) domain (Kishore and Reid, 1999). After recognising IgG- and IgM-containing 
immune complexes, C1q, in association with C1r and C1s complexes that yields C1 
molecule, triggers the classical pathway activation. However, C1q is not always 
dependent on the binding of IgG or IgM to target ligands, primarily pathogens, in order 
to perform its duty as a potent innate immune molecule. In addition to being the key 
molecule of the classical pathway, C1q has a broad range of functions that includes 
clearance of apoptotic and necrotic cells, sustenance of pregnancy, recognition of 
pathogens in an antibody-independent manner, immune cell modulation, and pruning 
of excess synapse during development (Kishore et al, 2004a; Nayak et al, 2014). The 
importance of C1q in human health has been highlighted by its involvement in a 
number of pathological conditions including lupus nephritis, a number of inflammatory 
disorders, Alzheimer’s disease, prion disease, and cancer.  
During the course of last two decades, a number of proteins of diverse origin 
have been shown to contain at least gC1q-like domain, and hence, identification of a 
C1q family (Ghai et al, 2007). The structural analysis of one of such C1q family 
member, adiponectin, revealed that the three dimensional structure of gC1q domain 
was remarkably conserved and overlapped with tumour necrosis factor (TNF) and 
related molecules, hence, recognition of a C1q-TNF superfamily (Scherer et al, 2003; 
Gaboriaud et al, 2003; Gaboriaud et al, 2011; Kishore et al, 2004b). 
Although the main source of the local synthesis of C1q has been attributed to 
the potent antigen presenting cells such as monocyte/macrophages and dendritic 
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cells, various types of proliferating and non-proliferating cells including malignant cells 
can also be included in the list of C1q producers (Kouser et al, 2015). Thus, there are 
a number of functions attributed to C1q that are not reliant on complement activation 
mediated by C1q (non-complement functions of C1q) (Nayak et al, 2014). 
In this volume, which highlights the structural and functional the complexities of 
human C1q, KBM Reid, one of the pioneers in the field, has elegantly provided a 
historical account of the field, together with many unanswered questions and what the 
future holds for this truly remarkable complement protein (1). Another review by Lu 
and Kishore examines important features of C1 complex that can perform exciting 
unexpected functions without involving complement activation (2). For instance, C1q, 
when bound to the Frizzled receptors, leads to activation of C1s, which cleaves 
lipoprotein receptor-related protein (LRP) 6 to trigger aging-associated Wnt receptor 
signalling (Naito et al, 2012). C1q binds to apoptotic cells and the activated C1 
proteases cleave nuclear antigens (Cai et al, 2015). The diversity of C1q ligands and 
C1 protease substrates makes C1q as well as C1 complex quite a versatile recognition 
and effector machinery beyond the territory of complement activation. In the continuing 
theme of structural and functional versatility of C1q, Ghebrehiwet et al emphasize the 
modular organisation of the gC1q domain (3), revealing the ‘secret of this functional 
diversity’, based on the modularity within each chain of gC1q domain i.e. ghA, ghB 
and ghC modules (Kishore et al, 2003). Within the gC1q domain, which is composed 
of the C-terminal ends of A, B and C chains, this review makes arguments for the A-
chain (ghA) to be most versatile module in terms of ligand binding (3).  
C1q binding to the CH2 domain of antigen-bound IgG and subsequent classical 
pathway activation depends on its close proximity to the Fc region of adjacent IgG; 
C1q does not bind (or binds with very weak affinity to) circulating IgG monomers. 
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Crucially, IgG CH2 domains contain Asp-297 N-linked glycan amenable to extension 
by terminal galactose and sialic acid residues. Using recombinant variants of CD20-
specific monoclonal antibody, rituximab, Perschke et al demonstrate that Fc-galactose 
enhances complement fixation, but only for IgG1 and IgG4, proposing a novel strategy 
to complement fixing ability of therapeutic antibodies (4).  Following up on the C1q-
IgG subclass interaction, Lilienthal et al have examined the parallel between murine 
IgG1 and human IgG4 subclasses (both capable of inhibiting hexamerisation of IgG1 
and IgG3 and subsequent C1q binding and classical pathway activation). The authors 
show that murine IgG1 suppresses IgG2a-mediated classical pathway activation. 
Since IgG subclass is of great importance in pathophysiology, galactose and sialic 
acid manipulation has therapeutic implications (5). It is worthwhile to note that 
allergen-based immunotherapy in allergic patients can give rise to increased IgG4 
levels while dampening specific IgE production; thus, IgG4 subclass polarisation also 
circumvents the classical pathways activation in allergen-desensitised patients. 
Moving on from immunoglobulin interaction of C1q to non-immune ligands, Donat et 
al examined the implications of C1q binding to cholesterol crystals as well as von 
Willebrand factor (vWF) with respect to cholesterol crystal clearance by macrophages 
(6).  Curiously, vWF bound cholesterol crystals via C1q, and the tripartite complex 
upregulated phagocytic and sensing receptors, such as MerTK, LRP-1, SR-A1, CD14, 
LAIR1 and PD-L1. vWF seems to interfere with the phagocytosis of cholesterol 
crystals and C1q complex. An assessment of pro-inflammatory cytokines revealed that 
vWF binding to C1q suppresses inflammatory response by macrophages, which may 
be relevant in atherosclerosis. El-Shami et al have reviewed the role of complement 
(and C1q) in chronic hepatitis C virus (HCV) infection and cryoglobulinemia (7) since 
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HCV-triggered complement activation is involved in liver fibrosis and type II 
cryoglobulinemia.  
The last two papers, from Roberta Bulla group, in the volume allude to the 
fascinating involvement of C1q in tumour (8-9). C1q is expressed in the 
microenvironment of various types of human tumours, including melanoma, prostate, 
mesothelioma, and ovarian cancers. C1q promotes tumour by encouraging their 
adhesion, migration, and proliferation in addition to angiogenesis and metastasis 
(Bulla et al, 2016). Agostinis et al now report that C1q is found in good amounts in the 
tumour microenvironment of asbestos-induced malignant pleural mesothelioma 
(MPM), where it can interact with hyaluronic acid (HA), an abundant tumour 
microenvironment component. C1q-HA interaction seems to work in favour of MPM 
cells, suggesting that C1q can be exploited by tumour for its progression and invasion 
(8).  In another study, Mangogna et al have used Oncomine and UALCAN database 
in order to ascertain whether the transcriptional expression of the C1q three chains 
has a prognostic relevance for glioma (9).  C1q is known to be expressed in the central 
nervous system and is considered a precipitation factor for neurodegeneration and 
neuroinflammation (Bonifati and Kishore, 2006).  The study reveals a positive 
correlation between higher levels of C1q expression and unfavourable prognosis in a 
diverse grade of gliomas, thus, giving a new dimension to C1q research. How C1q 
interacts with brain tumour cells as well as microglia and astrocytes in the context of 
gliomas needs further investigation. 
In conclusion, C1q remains an ever important molecule of complement and 
innate immunity. Its versatility and modularity seem to offer enormous physiological 
potential; sometimes, it can be exploited by pathogens and tumour to their end. Future 
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research in the area cancer, pregnancy, ageing and neuroinflammation is going to 
throw many pleasant surprises.  
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